ISELIN, N.J., March  23, 2026  (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases,

OTLK

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics Launches Public Stock Offering Amid Investigational Phase for Retinal Treatment

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>ISELIN, N.J., March  23, 2026  (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Outlook Therapeutics has announced a public stock offering to raise funds primarily for working capital and corporate purposes. This decision comes as the company navigates the investigational status of its treatment ONS-5010 in the U.S., while already achieving approval in Europe for retinal diseases, potentially impacting its market position.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Outlook Therapeutics initiates a public offering of common stock.</li><li>Offering subject to market conditions and unspecified terms.</li><li>Funds will primarily support working capital needs.</li><li>Company&#039;s treatment ONS-5010 is investigational in the U.S.</li><li>ONS-5010 approved in Europe for retina diseases.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>H.C. Wainwright &amp; Co. (N/A)</strong>: Acting as exclusive placement agent for Outlook Therapeutics&#039; offering.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news falls under &#039;Corporate Developments&#039; as it discusses a significant stock offering. This is crucial for OTLK&#039;s capital structure and operational funding, affecting investor perception and stock price.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Public offering may dilute current shareholder value.</li><li>Regulatory approval timelines could impact future stock performance.</li><li>Investor sentiment could be affected by market conditions surrounding the offering.</li><li>Strategic use of raised capital may bolster future growth.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Public offering announced on March 23, 2026.</li><li>Intended use of proceeds is for working capital and corporate purposes.</li><li>ONS-5010 is investigational in the U.S., with European approval already obtained.</li><li>H.C. Wainwright &amp; Co. is the placement agent for the offering.</li><li>The offering is subject to market conditions and no completion assurance.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>OTLK may see volatility due to the public offering; position cautiously.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">ISELIN, N.J., March  23, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=zg3CAJrYCmQdl9wX8xyo2GLlXFnEOFq24d1U6AF2NW6k3YFh_bfOsk_Tv4PRbDtM2-QpsgHqvurfw7LKRk5aGZfLlphmHhJpgmA0G9TilpL0RLZo1WhruQmudbC0xrE5" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OTLK">OTLK</a>), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>  <p>H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</p>  <p>Outlook Therapeutics intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.</p>  <p align="justify">The securities described above are being offered by Outlook Therapeutics pursuant to a "shelf" registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the "SEC") on March 28, 2024, and became effective on April 5, 2024. This proposed public offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the effective registration statement. A preliminary prospectus supplement and an accompanying prospectus related to the proposed public offering will be filed with the SEC and will be available on the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this proposed public offering may also be obtained, when available, by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at <a href="https://www.globenewswire.com/Tracker?data=247L5DfaJgSeSpabWm-h_JwT-0b35IIj_9NSXCyZWZ-yh7KGNl3jRMMCT2pq7imy5QiN9sXbWwoMKURfHkThUCnpGgUsfmPbmvoz8s_7LBq8JWgvE27XHxK1-9CuW9pjqHwzC_Ke4VhsE3XwEAFYy0ur1aSKx6HXkFTGtAD5l688JcbMOkxyA6JvgAr4Xwz-TozX_Cs_MM_jBqI-QHr_-6aCI5AXtqvdgzPLf-tdOuFU621dYXu5QIm4aT3qkiD4172mS5E4COtKoCN5fFawgdJKZgtjunOliHEJxCl_6wn9v_XemTIJhjQldPWr28CNpzfQ4M4EWCFgInmBi3Jhbe0SLolqqNfbUcI1g1-EXYJUOqWJBZcQFDcum-1qL_NHN0GYxVhlgnHPoCXagnzwX8wbnD_6us4uaQ0i0dt6Kt1WFBj4Zvppy5s6pVLWwhau9oq_m1fm-eQwzJ1aeOh8jk-ecAq1qv9KqniPdx3V4B_u9CS0WEOct1PzxbDKh5Q9aO5kms4lG4MFA5Gcty3mxAWpb004ISsfrqwysQuAgXgum61FJiWXRHxIB4gez1BE-DhMxsfoGUpu-2qRunH18x851i8bYU4EvZ5hUo_37OxDYWAUwlavJ5dU3VXT44h53FuNtZuJh6ikNGA0JwGdSJG-uB_SbrhgfwtjmYMVbyjW-hr9Llx-gGS5LMNbMIPXfaSHAFASlMsoxLbCgahQPRDzC2uRbWWRVHTKOhURmJ_Rd0iN2LyrvXBS7539BY36yPAm7MlqgOocK6ab7PxBNQ==" rel="nofollow" target="_blank">placements@hcwco.com</a>.</p>  <p align="justify">This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>  <p align="justify"><strong>About Outlook Therapeutics, Inc.</strong><br></br></p>  <p align="justify">Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA&#x2122; (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA&#x2122; (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA&#x2122; (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.</p>  <p align="justify">In the United States, ONS-5010/LYTENAVA&#x2122; (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA&#x2122;, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.</p>  <p><strong>Forward-Looking Statements</strong></p>  <p align="justify">This press release contains statements that may or are considered "forward-looking statements." All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "expect," "may," "on track," "plan," "potential," "target," "will," or "would" the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include statements regarding, among others, Outlook Therapeutics' intention to conduct a public offering and sale of securities, the timing and size of the proposed public offering, the completion of the proposed public offering, the expected use of proceeds from the proposed public offering as well as the potential of ONS-5010/LYTENAVA&#x2122; as a treatment for retina diseases, the potential for ONS-5010 to receive approval from the FDA, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include fluctuations in Outlook Therapeutics' stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as supplemented by subsequent reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the global geopolitical conflict, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.</p>  <p><strong>Investor Inquiries:<br></br></strong>Jenene Thomas<br></br>Chief Executive Officer<br></br>JTC Team, LLC<br></br>T: 908.824.0775</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3NzEzMCM3NDk5MDEyIzIwMjg4MjI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OWM1ZTQ3OTUtNTVlOS00YjViLTlkMDctNmQ2NzkwOTJmYjQ2LTEwNDAzOTMtMjAyNi0wMy0yMy1lbg==/tiny/Outlook-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/cbff3302-f8d2-466a-beff-8c33252f9c70"><img src="https://ml.globenewswire.com/media/cbff3302-f8d2-466a-beff-8c33252f9c70/small/otlk-png.png" border="0" width="150" height="40" alt="Primary Logo"></img></a></p>

Outlook Therapeutics has announced a public stock offering to raise funds primarily for working capital and corporate purposes. This decision comes as the company navigates the investigational status of its treatment ONS-5010 in the U.S., while already achieving approval in Europe for retinal diseases, potentially impacting its market position.

Outlook Therapeutics Announces Proposed Public Offering

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News